ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1415

Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study

Mona Alotaibi1, Roxana Coras2, Dimitrios Pappas3, Ted Mikuls4, Joel Kremer5, Geoffrey Thiele6, mohit jain1 and Monica Guma7, 1Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, 2University of California San Diego, San Diego, CA, 3CorEvitas, LLC, Waltham, MA, 4Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5The Corrona Research Foundation, Delray Beach, FL, 6University of Nebraska Medical Center, Omaha, NE, 7UCSD, La Jolla, CA

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, Biomarkers, metabolomics, rheumatoid arthritis, TNF-blocking Antibody

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier in the course of rheumatoid arthritis (RA) could help reach the goal of remission. We hypothesized that circulating bioactive lipids at baseline would identify specific metabolic profiles that predict patient response to therapy and would define elements of metabolic pathobiology in arthritis.

Methods: Bioactive lipids were measured in plasma from two cohorts of RA patients from the CorEvitas (formerly known as Corrona) CERTAIN registry at baseline prior to treatment with TNF inhibitors (all biologic naïve, N=102) or anti-IL6 (all previously exposed to biologics, N=114). Response to treatment was categorized by minimal clinically important difference (MCID) in Clinical Disease Activity Index (CDAI) at 6 months after treatment initiation. Patients had to have a 6 month follow up visit. Liquid chromatography (LC) system coupled with high resolution QExactive orbitrap mass spectrometer (LC/MS) was used for bioactive lipids profiling. Around 300 spectral features were identified as potential oxylipins by searching against an in-house MS/MS library. Logistic regression analyses adjusted for gender, age and BMI was perfomed using R software.

Results: 102 patients (average age 54, standard deviation [SD] 12.6, 82% female [83], average BMI 29.7, SD 6.7, average CDAI 27.1, SD 13.7) starting anti-TNF therapy and 114 patients (average age 57, SD 13, 90% female [102], average BMI 30.5, SD 7.4, average CDAI 28.7, SD 13.8) starting tocilizumab were analyzed. Twenty-five oxylipins discriminated between RA patients classified as anti-TNF responders (R, n = 74) and non-responders (NR, n = 28). The anti-inflammatory SPM maresin 2 was increased in R (OR 1.7; 95%CI 1.07–2.9), and oxylipins 15d PGJ2 (OR 0.4; 95%CI 0.2–0.8), and 5,6-diHETE (OR 0.5; 95%CI 0.3–0.9) were decreased in R, among other metabolites Figure 1 and 2. Twenty different metabolites discriminated anti-IL6 R (n=73) and NR (n=41) as shown in Figure 1 and 2. The anti-inflammatory oxylipin 14-15EET (OR 1.7; 95%CI 1.05–2.7) and 8-iso-PGF1a (OR 1.8; 95%CI 1.07–3.1) were increased in R, whereas the pro-inflammatory oxylipins 16-HETE (OR 0.4; 95%CI 0.2–0.9) and 5S-HpETE (OR 0.5; 95%CI 0.26–0.95) were decreased in R.

Conclusion: Circulating bioactive lipid analysis using LC/MS provided a rapid analysis of a wide range of metabolites and can be used to describe metabolic signatures that predict response to therapies. These results lay the groundwork for more deliberate investigations of novel metabolic-based interventions to predict response to therapy and reduce arthritis morbidity.

Supporting image 1

Figure 1.Volcano plots visualizing baseline metabolites associated with responders vs. non responders in a) anti-TNF and b) anti IL-6 therapy groups. Results are derived from multivariate logistic regression analysis of baseline metabolites and response to treatment categorized by MCID. Data plotted as the metabolite against its statistical significance, respectively reported as odds ratio (OR) and -log10(pvalue)

Supporting image 2

Figure 2. Forest plot visualizing baseline metabolites associated with responders vs. non responders in anti-TNF and anti-IL6 therapy groups. Results are derived from multivariate logistic regression analysis of baseline metabolites and response to treatment categorized by MCID in CDAI


Disclosures: M. Alotaibi, None; R. Coras, None; D. Pappas, CorEvitas, Novartis, Sanofi, Genentech, Roche, AbbVie; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc; J. Kremer, CorEvitas; G. Thiele, None; m. jain, Sapient; M. Guma, Pfizer, Novartis, Gilead, Sonoma Bio, Genentech.

To cite this abstract in AMA style:

Alotaibi M, Coras R, Pappas D, Mikuls T, Kremer J, Thiele G, jain m, Guma M. Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/different-bioactive-lipid-profile-predicts-response-to-tnf-or-il6-inhibitors-in-rheumatoid-arthritis-result-of-the-corevitas-certain-comparative-effectiveness-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-bioactive-lipid-profile-predicts-response-to-tnf-or-il6-inhibitors-in-rheumatoid-arthritis-result-of-the-corevitas-certain-comparative-effectiveness-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology